Clarkston Consulting and RTSM provider 4G Clinical in collaboration deal

Clarkston Consulting enters into collaboration deal with 4G Clinical for randomization and trial supply management. (Getty Images)

Life sciences consulting firm Clarkston Consulting said it has entered into a collaboration deal with 4G Clinical, which specializes in randomization and trial supply management (RTSM).

Under the agreement, the two firms said they look to create a comprehensive client experience as the life sciences industry undergoes transformational shifts in clinical operations. The two will also co-author industry reports and white papers on trends, drivers and strategies that affect clinical trial professionals.

Financial terms of the deal weren’t disclosed.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“As clinical trial complexity increases, the underlying technologies and capabilities that support the journey of a drug to market must evolve with it,” Dave Kelleher, 4G’s chief executive, said in a statement. The partnership with Clarkston will provide innovative capabilities and enable “better outcomes for the patient and the business,” he added.

RTSM systems support the randomization of patients into different arms of a trial and the supply of study drugs to sites. The technology has evolved from the phone-based systems of the 1990s, known by the abbreviation IVRS, to the web-based platforms in use today.

4G’s competitors include trial technology powerhouses like Medidata and Parexel.

Suggested Articles

Scott Gottlieb has slipped right back into his old ways, becoming "special partner" at his old life science VC firm New Enterprise Associates.

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.